Poly cystic ovarian syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Patients who receive 2 liters of synbiotic pomegranate juice each week, which consists of pomegranate juice, enriched with inulin and lactobacillus, in the form of disposable bottles f
Treatment - Other
Placebo
Patients who receive 2 liters of synbiotic pomegranate juice each week, which consists of pomegranate juice, enriched with inulin and lactobacillus, in the form of disposable bottles for 8 weeks.
Patients who receive 2 liters of pomegranate juice each week, in the form of disposable bottles for 8 weeks.
Patients who receive 2 liters of synbiotic juice each week, which consists of placebo, enriched with inulin and lactobacillus, in the form of disposable bottles for 8 weeks.
Patients who receive 2 liters of placebo juice each week, which consists of pomegranate flavore, in the form of disposable bottles for 8 weeks.
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
15 Years to 48 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria PCOS could be diagnosed, after the exclusion of related disorders, by two of the following three features: Oligomenorrhea (Less Than 6-9 Menses per Year) or amenorrhea (no vaginal bleeding for at least 6 months); Clinical findings: Increased blood androgen levels (hirsutism higher than 7 or acne), or increased blood testosterone levels (testosterone levels above 2 nmol / l); Polycystic ovaries in ultrasound (presence of 12 or more cysts with a diameter of 9.2 mm inside one or both ovaries or the size of the ovary 10 cm 3 or more); BMI>18; Having permission the doctor and informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Other medical conditions related to excess androgens such as increased blood prolactin; nonclassical congenital adrenal hyperplasia; Cushing's syndrome; androgen-producing tumors and acromegaly wemon with severe diseases of the stomach, intestines, heart; kidne; liver; lung; chronic; autoimmune; inflammatory and AIDS; Patients undergoing chemotherapy; smokers; Lactating women Patients treated with corticosteroids and antibiotics; The use of supplements of vitamins; minerals and antioxidants; Those taking hormone pills or supplements; Patients using insulin to treat diabetes; Patients with a special diet; Patients with specific exercise program
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Cholestrol. Timepoint: Before and 2 month after intervention. Method of measurement: Autoanalyzer.;Triglyceride. Timepoint: Before and 2 month after intervention. Method of measurement: Autoanalyzer.;HDL-C. Timepoint: Before and 2 month after intervention. Method of measurement: Autoanalyzer.;LDL-C. Timepoint: Before and 2 month after intervention. Method of measurement: Autoanalyzer.;Health-related quality of life in polycystic ovary syndrome patients. Timepoint: Before and 2 month after intervention. Method of measurement: Questionaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mensturation cycle. Timepoint: Before and 2 month after intervention. Method of measurement: Questionare. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Esmaeilinezhad
Shiraz University of Medical Sciences
Outcome results
None listed